A Phase 2 interventional study of brimonidine/timolol fixed combination in Ocular Hypertension, sponsored by Allergan. Completed at 1 site in United States. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2011-05-30.
Sponsored by Allergan (part of AbbVie) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 80 studies in Ocular Hypertension by AbbVie — none open to participants now, 1 under way, none of them phase 3. Ocular Hypertension · AbbVie.
Among the 80 studies in Ocular Hypertension by AbbVie, this one is the 53rd largest by enrollment of the 58 interventional ones that give a count, is one of 2 that started in 1999, is one of 8 in phase 2, and was the 3rd registered.
659 studies on the registry are indexed under Ocular Hypertension; 48 are open to participants now.
Browse Ocular Hypertension studies →None of the 80 studies in Ocular Hypertension by AbbVie is open now. The open studies under Ocular Hypertension, anywhere →
Of the 36 Ocular Hypertension studies recruiting now, 31 (86%) set no upper age limit and none (0%) stop at 75 or younger; 1 takes children under 18; 4 take healthy volunteers.
This study: 21 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
80 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 12 · Phase 3 23 · Phase 4 21
First in 1999; this study’s year is marked. 2 started in 1999.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 73 is below the median of 114 across 520 interventional studies indexed under Ocular Hypertension.
Median enrollment 215 across the 58 interventional studies, 576 across the 22 observational. Of the 78 that completed or were terminated, 58 (74%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Allergan, one of the names counted as AbbVie. Under that name alone:
Allergan is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 93 completed or terminated interventional studies of FDA-regulated products, 91 (98%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 80 studies in Ocular Hypertension by AbbVie, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the safety and efficacy of Brimonidine/Timolol Fixed Combination in patients with glaucoma or ocular hypertension
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
IOP
The record gives a start of Jul 1999, a primary completion of Aug 1999 and a completion of Aug 1999. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.